Navigation Links
UCLA cancer researchers discover new signaling pathway that controls cell development and cancer

Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.

The new pathway, part of a global DNA damage response, turns off 136 genes, including some that have are known to cause cancer because, unchecked, they can promote aberrant cell division.

"It's important to make sure this pathway works correctly, because it prevents cells from dividing excessively" said Dr. Michael Teitell, a professor of pathology and laboratory medicine, a Jonsson Cancer Center researcher and senior author of the study. "When this pathway is defective, cancers can happen."

The study appears in the Sept. 24, 2010 issue of the peer-reviewed journal Molecular Cell.

A widely used oral diabetes drug, Metformin, is known to activate the identified pathway and could possibly be protective against cancer in certain pathway defects. It's been shown through epidemiological studies, Teitell said, that diabetes patients on Metformin have lower incidences of lymphoma and leukemia, possibly because the drug is regulating pathway operation.

Additionally, new therapies that target the pathway could be developed to correct newly identified defects, thereby blocking the formation of cancer.

The study also revealed an unknown DNA damage response outcome. It is generally agreed that one of three things happen to cells in response to DNA damage cells are temporarily arrested from growing so the damage can be repaired, cells go quiet and permanently stop dividing so they don't pass on the DNA damage, or cells simply die, a process known as apoptosis.

Teitell's study uncovered a fourth option - the DNA damage itself drives less mature cells to develop into more mature cells, in this case into antibody-secreting plasma cells, by turning off the 136 genes identified in the study. Defects in the newly discovered cell signaling pathway don't allow cells to progress to their natural end point by blocking normal gene silencing. The less mature cells become stuck where they are, dividing too rapidly and potentially resulting in lymphoma or leukemia.

Usually DNA damage is thought to be associated with environmental factors, such as exposure to too much sun or to toxic chemicals. Chemotherapy also damages cell DNA. However, Teitell and his team discovered that a normal process, the creation of antibodies to battle infection, results in physiologic DNA damage that also activates the identified signaling pathway.

Teitell, in previous studies, discovered that the gene TCL1 can cause B-cell cancers, including various types of lymphomas, if it is not turned off at the right time in development. Activation of this new signaling pathway, in fact, is the mechanism that shuts the TCL1 oncogene down at the appropriate time. If a pathway defect develops, TCL1 and the other 135 genes remain elevated and cancer may arise.

B-cells are lymphocytes that play a large role in immune responses and they make antibodies in response to infection or vaccination. They divide at the highest rate in the human body, faster than skin, hair or cells of the gastrointestinal tract. In making antibodies to fight infection or in response to a vaccine, these rapidly proliferating cells undergo DNA damage in order to make better, more effective antibodies. The body, in effect, is trading off the potential harm caused by added DNA damage in order to effectively ward off a more immediate invader.

The rapid cell cycling process that occurs during antibody assembly and testing by the immune system needs to be halted at the right time, Teitell said. The body naturally turns off that process after about two to three weeks. A defect in the new pathway interrupts that natural stop signal and blocks the production of effective antibody-producing cells, the plasma cells.

Mara Sherman, the first author of the study who worked as a graduate student in Teitell's lab, said the paper "reflects an exciting and emerging connection between DNA damage response pathways and cell differentiation."

"Our work points to this DNA damage-response pathway as a potential, novel therapeutic target for the treatment of B-cell lymphoma," Sherman said. "Combined with several intriguing recent studies, our work further suggests that pathways with established roles in genome maintenance may also drive the differentiation of stem and progenitor cell populations."

Patients at risk for developing B-cell related cancers could be screened for genes that, when not turned off, are a signature indicating pathway defects. The pathway also could be playing a role in the development of lung, colon and other major cancer types, Teitell said.

Going forward, Teitell and his team will further study the pathway to detail all aspects of its operation so new therapies can be developed to fix it when something goes wrong.


Contact: Kim Irwin
University of California -- Los Angeles

Related medicine news :

1. Patients with cancer who stop hospice care boost health-care costs
2. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
3. Mammograms Cut Breast Cancer Death Rates, But Only Modestly: Study
4. David Cheresh receives top award for cancer metastasis research
5. 70 percent of women likely to experience sexual problems after breast cancer
6. Physical limitations of breast cancer survivors
7. Synthetic lethality strategy improves molecularly targeted cancer therapy
8. U of M Masonic Cancer Center receives $26 million to lead national BMT cancer research
9. War on cancer produces collateral damage to the heart
10. Cholesterol drug may have role in treating prostate cancer
11. Mayo-led researchers discover genetic variants modifying breast cancer risk
Post Your Comments:
(Date:12/1/2015)... San Diego, CA (PRWEB) , ... December 01, ... ... simplicity and scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of ... Ease® mobile imaging results enhancements at the Radiological Society of North America (RSNA) ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator ... the latest addition to the devices for sale in the United States. Clarity ... and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech ... through membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, ... has spent a significant amount of time in Sweden since joining PartnerTech based ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. This ... patient care experience, and propose exciting enhancements to the medical landscape. , The ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Germany , December 1, 2015 /PRNewswire/ ... leading global manufacturer of eye and gaze tracking solutions, ... SMI remote eye trackers as a component of its ... concussions, eye sight, and medical and performance issues in ... part of SMI,s mass-market-ready eye tracking platform, which is ...
(Date:12/1/2015)... 2015 --> ... Leeuwenhoek Hospital (NKI-AVL), among the world,s largest and ... Gamma Knife® Icon™, the company,s latest generation stereotactic ... --> --> With the option ... Leksell Gamma Knife Icon offers greatly enhanced flexibility ...
(Date:12/1/2015)... Dec. 01, 2015 ... "Drug Delivery Technology Market 2015 - Forecast ... --> ) has announced the addition ... - Forecast to 2020" report to their ... ) has announced the addition of the ...
Breaking Medicine Technology: